Cara Therapeutics reported that all tested tablet strengths of Oral CR845 were pharmacologically active, safe and well tolerated after single and multiple dose administration BOONTON, NJ, USA I...
NAi Therapeutics, a licensee of RNAi specialist Marina Biotech, reported positive results from its so-called DNAi-based candidate PNT2258 for non-Hodgkin lymphoma.
SMARTICLES(R) Formulated PNT2258 Achieved Meaningful Therapeutic Outcomes Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare...
Nanotechnology's effect on drug delivery is becoming more and more widespread with many projects around the globe dedicated to finding a way to bring it to the market. But once it reaches the market, nanomeds face another hurdle: manufacturing. Because the particles involved in these systems are so different in scale from other drugs on the market, drugmakers will need a way to make them in bulk and at a low cost, though still highly specific in form and function.
Insys Therapeutics, a combination drug developer and delivery specialist, won an orphan designation from the FDA for a gastric cancer treatment that delivers paclitaxel trapped in liposomes to make the common cancer drug more soluble and less toxic.
PHOENIX, AZ -- (Marketwired) -- 12/09/14 -- Insys Therapeutics, Inc. (NASDAQ: INSY), a specialty pharmaceutical company that is developing and commercializing innovative drugs and novel drug delivery...
Acquisition Augments Merck's Strong Foundation and Opportunity for Growth in Hospital Acute Care Market Monday, December 8, 2014 7:00 am EST KENILWORTH, N.J. & LEXINGTON, Mass.--(BUSINESS...
> NuvOx Pharma snagged an exclusive license from the University of Arkansas for a dodecafluoropentane emulsion that can reduce brain damage from stroke by over 80%. Release > Hovione filed an...
CORK, Ireland, November 27, 2014 /PRNewswire/ -- Hovione announced today it has filed its first Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA). This event...
NuvOx Pharma exclusively licensed United States Patent Application 20140004099 entitled "DODECAFLUOROPENTANE EMULSION AS A STROKE AND ISCHEMIA THERAPY" from the University of Arkansas for Medical...
